
Opinion|Videos|June 26, 2024
Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial
Results from the monarchE trial are analyzed by Hope Rugo, MD, and Joyce O'Shaughnessy, MD.
Advertisement
Video content above is prompted by the following:
- Abemaciclib is recommended by NCCN in this setting based on the monarchE trial, which recently released its 5-year long-term data in January.
- Describe the updated survival data, including both invasive disease-free survival and overall survival. How have these survival rates evolved with each annual analysis?
- Please highlight the follow-up time of patients.
- Are there specific subgroups of patients within the monarchE trial who derived particular benefit from the addition of abemaciclib?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Ways ACOs Can Improve Care, Achieve Meaningful Savings
2
Long-Term Remission in Ph-Negative B-ALL With Sequential CAR T, ASCT
3
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
4
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
5












































